Current investments

Suir Valley Ventures logo

Sure Valley Ventures

Sure Valley Ventures is a venture capital fund focused on investing in the software technology sector. Specifically, it focuses on the high growth artificial intelligence (AI), augmented/virtual reality (AR/VR) and internet of things (IoT) sectors. This will enable investors to gain access to potentially high growth companies through a publicly listed company.

Sure Valley Ventures portfolio companies:

Admix
Programmatic monetization platform for AR & VR
The first monetization platform for VR/AR developer. Enables non-intrusive, programmatic product placements within content.
View Profile
Ambisense
Leader in real time, continuous monitoring of gas at industrial sites
Focus on EPM of brownfield sites and oil and gas Real-time analytics – data and AI Expanding from UK into key European markets
View Profile
Artomatix
AI platform to automate 3D content creation for AR/VR, AAA video games and movies. Ai for the creative industries Launched product in March and now has 140 customers in their pipeline
View Profile | Exit: Unity
Buymie
Buymie uses AI to provide consumers with access to multiple large retailers.
View Profile
CameraMatics
The leader in cameramatics solutions for commercial transit fleets
Ongoing trial with the fleet of large US FMCG companies Evidence of support from planned German / EU legislation Series A financing by the end of 2019
View Profile
Getvisibility
Getvisibility has developed proprietary software that uses artificial intelligence to discover classify and protect unstructured data typically contained in PDFs, spreadsheets, emails and text documents.
View Profile
Immersive VR Education
Software platform for educators and corporate companies to create educational VR content.
Listed on AIM in March valued at £19m (LON:VRE)
Apollo 11 selected as part of Oculus Go launch collection
View Profile
Accelerator: NDRC@ArcLabs
Sure Valley Ventures is already tapping the next generation of deep tech companies via its investment in NDRC@ArcLabs. NDRC builds and invests in very young digital companies, or startups offering them early stage investment and development.

With more than ten years’ experience, NDRC’s key skill lies in finding companies and teams with the potential to grow internationally.

Once a company joins NDRC, the team works intensively with each, over a short time frame, to help them understand what value their company can offer customers, their strategy for growth and getting them ready to meet the demands of both investors and customers.
Nova Leah
Leading cyber security assessment and protection for medical devices. Supported by FDA requirements in the USA Broad application for any IoT device Initial market sales – medical devices.
View Profile
VividQ is a Cambridge-based deep-tech company with world-leading expertise in 3D holography. Its patented software powers holographic display in AR/VR headsets, smart-glasses, and automotive Head-Up Displays developed by global blue chip technology companies.
View Profile
Volograms are on a mission to bring reality capture closer to everyone and democratize volumetric content creation. Volograms enable the capture of volumetric holograms (volograms) of real people for all kinds of immersive experiences apps and social media. Volograms are a team of creatives and technology experts in 3D Vision Augmented and Virtual Reality building the first software only hardware-agnostic scalable volumetric video creation platform.
View Profile
WarDucks
Gaming studio creating immersive games across leading AR & VR platforms
Last release was 2nd most popular title on Samsung Gear VR
Major mobile AR game ‘Smooshy Mushy’ launched Q4 2018
View Profile
WIA
Leading IoT developer with over 30,000 utilising their technology
Valuable eco-system being created Other trade sales of developer platforms
View Profile

Eco Atlantic

Eco Atlantic is a TSX-V and AIM listed Oil & Gas exploration and production Company with interests in Guyana and Namibia where significant oil discoveries have been made.

“Eco” aims to deliver material value for its stakeholders through oil exploration, appraisal and development activities in stable emerging markets, in partnership with major oil companies, including Tullow, Total and Azinam.

In Guyana, Eco Guyana holds a 15% working interest alongside Total (25%) and Tullow Oil (60%) in the 1,800 km2 Orinduik Block in the shallow water of the prospective Suriname-Guyana basin. The Orinduik Block is adjacent and ip to ExxonMobil and Hess Corporation’s Stabroek Block, on which thirteen discoveries have been announced and over 6 Billion BOE of oil equivalent recoverable resources are estimated. First oil production is expected from the deep-water Liza Field in 2020.

 Jethro-1 was the first major oil discovery on Orinduik Block. The Jethro-1 encountered 180.5 feet (55 meters) of net high-quality oil pay in excellent Lower Tertiary sandstone reservoirs which further proves recoverable oil resources. Joe-1 is the second discovery on the Orinduik Block and comprises high quality oil-bearing sandstone reservoir with a high porosity of Upper Tertiary age. The Joe-1 well encountered 52 feet (16 meters) of continuous thick sandstone which further proves the presence of recoverable oil resources. 

In Namibia, the Company holds interests in four offshore petroleum licences totalling approximately 25,000km2 with over 2.3bboe of prospective P50 resources in the Walvis and Lüderitz Basins.  These four licences, Cooper, Guy, Sharon and Tamar are being developed alongside partners Azinam and NAMCOR. Eco has been granted a drilling permit on its Cooper Block (Operator).

Portage Bio

Portage is comprised of scientists, clinicians, and business executives who, as a collective, have created a better model for biotechnology product development.

They nurture the creation of early- to mid-stage, first- and best-in-class therapies for a variety of cancers, by providing funding, strategic business and clinical counsel, and shared services, to enable efficient, turnkey execution of commercially-informed development plans.

In collaboration with their subsidiaries, they create viable product development strategies, to cost-effectively deliver best-in-class R&D, clinical trial design, and financial and project management, to ultimately build value and support commercial potential.